A study by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) shows that a combination of tiotropium bromide with a low dose of inhaled corticosteroid (ICS) provides better asthma control than doubling the dose of ICS and is as effective as a salmeterol/ICS combination. Patients taking the tiotropium combination gained an additional 48 symptom-free days per year compared to an additional 19 symptom-free days gained by doubling the ICS dose. The study involved more than 200 adults with poorly controlled asthma. Read the NHBLI press release.
NHLBI study shows tiotropium/ICS combo effective for asthma
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA
